Presentations and Interviews

  Presentation Media Date

Follow us – Stay updated

November 22, 2021

AlzeCure Pharma – Redeye Life Science Day

November 11, 2021

AlzeCure update on the latest developments – Interview with CEO Martin Jönsson about the company, its projects developments in Alzheimer’s and pain, and future plans.

October 22, 2021

Alzecure presents at Healthcare Innovation Summit

October 7, 2021

Alzecure Pharma – Naventus Life Science Summit

September 29, 2021

Characterization of positive allosteric modulators of TrkB for the treatment of depression

October 2-5, 2021

Aktiespararna interview CEO Martin Jönsson – latest quarterly report and future prospects. (Swedish)

September 20, 2021

AlzeCure Pharma – Aktiedagen Stockholm. (Swedish)

September 7, 2021

Strategy Update on Alzheimer’s Disease & NeuroRestore

September 1, 2021

Alzheimer’s disease and the neurotrophins BDNF/NGF by Prof. Maria Eriksdotter M.D., PhD

September 1, 2021

Company Overview & Vision by Martin Jönsson CEO

September 1, 2021

NeuroRestore Background and evolution by Dr Pontus Forsell, PhD Head of Discovery & Research

September 1, 2021

Development plan for NeuroRestore ACD856 by Dr Johan Sandin, PhD Chief Scientific Officer

September 1, 2021

ACD856 – a novel positive allosteric modulator of Trk-receptors in clinical development for the treatment of Alzheimer’s disease; Scientific presentation at AAIC, July 26-30, 2021

July 29, 2021

About AlzeCure’s origin and development – An embryo that can be something big – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish)

June 11, 2021

About Alzstatin and drugs for Alzheimer’s disease – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish)

June 11, 2021

About suffering from Alzheimer’s disease, diagnostics, care today and future needs – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish)

June 11, 2021

Negative Allosteric Modulators of TrkA for the Treatment of Pain – Scientific presentation at the IASP conference on pain, June 2021

June 11, 2021

ACD440 – A Novel TRPV1 Antagonist for the Topical Treatment in Neuropathic Pain – Scientific presentation at the IASP conference on pain, June 2021

June 9, 2021

Alzecure: CEO Martin Jönsson present at Redeye Growth Day

June 7, 2021

CEO Martin Jönsson after the company’s annual meeting

May 17, 2021

TrkA- NAM – Project in osteoarthritis & other severe pain conditions by Head of Discovery & Research Pontus Forsell, May 11, 2021

May 11, 2021

ACD 440 – A novel VR1 antagonist for neuropathic pain by CSO Johan Sandin, May 11, 2021

May 11, 2021

Chronic Pain – a high unmet medical need by CMO Märta Segerdahl, May 11, 2021

May 11, 2021

Company overview and goals by CEO Martin Jönsson, May 11, 2021

May 11, 2021

Update on Progress in the Painless Platform, May 11, 2021

May 11, 2021

Alzecure: Interview with CEO Martin Jönsson and CSO Johan Sandin (video)

April 20, 2021

Alzecure: Interview with CEOMartin Jönsson (video). (Swedish)

March 1, 2021

Interview with Martin Jönsson CEO in Aktiespararna’s analysis guide

February 8, 2021

Improving Quality of Life for People with Neurodegenerative Diseases – Stockholm Researchers and Health Tech Companies

January 14, 2021

CEO Martin Jönsson presentation, Aktiedagen Lund

January 27, 2021

Interview with Johan Sandin (CSO) in Aktiespararna’s analysis guide

January 22, 2021

Alzecure: CEO Martin Jönsson presents at Redeye Life Science Day 2020

December 1, 2020

Scientific presentation on the NeuroRestore® candidate ACD856 presented at the CTAD conference

November 4-7, 2020

Scientific presentation on Alzstatin presented at the CTAD conference

November 4-7, 2020

Scientific and market update with professor Henrik Zetterberg on Alzheimer’s disease, bio-markers, potential future treatments, including Alzstatin and AlzeCure

September 30, 2020

AlzeCure presentation with CEO Martin Jönsson at Aktiespararna (Swedish)

September 8, 2020

AlzeCure Science & Market update about Alzheimer’s diseas and NeuroRestore (Swedish)

September 1, 2020

Welcome to AlzeCure … Introduction film about the company (Swedish) – 1 minute

CEO presentation at the annual meeting (Swedish)

May 20, 2021

Scientific presentation about ACD856, a positive modulator of neurotrophin signaling reverses scopolamine- or age-induced cognitive deficits

April 2-5, 2020

Get to know AlzeCure’s CEO Martin Jönsson – Redeye interview (Swedish)

March 19, 2020

AlzeCure presentation with CEO Martin Jönsson at Aktiespararna (Swedish)

March 16, 2020

About the Alzstatin® project Disease modifying treatment of Alzheimer’s disease

About Alzheimers disease

February 27, 2018

About the project NeuroRestore®, symptomatic treatment of cognitive disorders such as in Alzheimer’s disease

February 27, 2018